International Journal of Medical Advances and Discoveries

ISSN 2756-3812

International Journal of Medical Advances and Discovery ISSN 2756-3812 Vol. 1 (1), pp. 001-009, December, 2010. © International Scholars Journals

Full Length Research paper

A tumor selective chemotherapy. Can this be managed by an algorithm based on the non-Markovian population dynamics?

Dmitry A. Kuznetsov1,2, Sergey A. Roumiantsev3,4, Majid Fallahi 3, Nima Amirshahi1, Andrey V. Makarov2, Karina S. Kardashova5

1N.N.Semenov Institute for Chemical Physics, Russian Academy of Sciences, Kosygin St.4, Moscow 119991, Russia 2Department of Medicinal Nanobiotechnologies, N.I.Pirogov Russian State Medical University, Ostrovityanov St.1, Moscow 117997, Russia

3Department of Molecular and Experimental Hematology, Oncology and Immunology, Federal Research Center of Pediatric Hematology, Oncology and Immunology, Leninsky Prospect 117, Moscow 117997, Russia

4Department of Clinical Hematology, N.I.Pirogov Russian State Medical University, Ostrovityanov St.1, Moscow 117997, Russia

5Department of Fundamental and Applied Neurobiology, V.P.Serbsky Institute for Social and Forensic Psychiatry, Kropotkinsky Pereulok, 23, Moscow 119992, Russia

Accepted 15 October, 2010

Abstract

A non-Markovian theory of population dynamics is to simulate the anti-cancer drug distribution between malignant and the hosting normal cell pools. The model takes into account both the cell life span and the proliferation rate differences. This new simulation approach looks promising for its potential to optimize a chemotherapeutic strategy by choosing the scheme with a higher degree of the drug-tumor selectivity.The pre-test designed simulation mode fits nicely the experimental data on Porphylleren-MC16 (PMC16) pharmacokinetics patterns including the allometric plots revealed for this new medicinal porphyrined-fullerene nanoparticle possessing some anti-cancer potential and intervening into the oxygen-independent ATP production mechanisms.

Key words: chemotherapy, population dynamics, drug-tumor selectivity.